KCM
DSGN icon

Kennedy Capital Management’s Design Therapeutics DSGN Stock Holding History

Kennedy Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.56M Buy
384,036
+112,482
+41% +$1.4M 0.1% 307
2026
Q1 		$2.89M Buy
271,554
+221,531
+443% +$2.24M 0.06% 376
2025
Q4 		$469K Buy
50,023
+20,612
+70% +$161K 0.01% 513
2025
Q3 		$221K Buy
29,411
+14,401
+96% +$72.1K ﹤0.01% 553
2025
Q2 		$50.6K Buy
15,010
+627
+4% +$2.35K ﹤0.01% 581
2025
Q1 		$55.5K Buy
14,383
+117
+0.8% +$558 ﹤0.01% 642
2024
Q4 		$88K Buy
+14,266
New +$82.6K ﹤0.01% 669

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Kennedy Capital Management's DSGN Position: Q2 2026 in Review

Kennedy Capital Management increased its Design Therapeutics (DSGN) stake by 41% in Q2 2026, buying an estimated $1.4M and bringing the position to 384,036 shares worth $5.56M. The position accounts for 0.1% of the portfolio, ranked #307.

Kennedy Capital Management first reported a position in DSGN in Q4 2024 and has held it in 7 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Kennedy Capital Management held 384,036 shares of Design Therapeutics worth $5.56M as of Q2 2026.
  • Kennedy Capital Management bought 112,482 Design Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Design Therapeutics made up 0.1% of Kennedy Capital Management's portfolio in Q2 2026, its #307 holding.
  • Kennedy Capital Management first reported a position in Design Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.